(D-ALA7)-ANGIOTENSIN I/II (1-7)
- Product Name
- (D-ALA7)-ANGIOTENSIN I/II (1-7)
- CAS No.
- 159432-28-7
- Chemical Name
- (D-ALA7)-ANGIOTENSIN I/II (1-7)
- Synonyms
- DA-7;A-779;DRVYIHA;A 779 TFA;A 779(3TFA);A 779?, >98%;A-779 ，E0039;ASP-ARG-VAL-TYR-ILE-HIS-D-ALA;(D-ALA7)-ANGIOTENSIN I/II (1-7);(D-Ala?)-Angiotensin I/II (1-7)
- CBNumber
- CB3151299
- Molecular Formula
- C39H60N12O11
- Formula Weight
- 872.97
- MOL File
- 159432-28-7.mol
(D-ALA7)-ANGIOTENSIN I/II (1-7) Property
- Density
- 1.45±0.1 g/cm3(Predicted)
- storage temp.
- -15°C
- pka
- 3.29±0.10(Predicted)
- form
- lyophilized powder
- color
- white to off-white
- Water Solubility
- ≥ 29.1mg/mL in Water with gentle warming
- Sequence
- Asp-Arg-Val-Tyr-Ile-His-{d-Ala}
Safety
- HS Code
- 2933.29.4300
N-Bromosuccinimide Price
- Product number
- SML1370
- Product name
- A-779 trifluoroacetate salt
- Purity
- ≥98% (HPLC)
- Packaging
- 5MG
- Price
- $118
- Updated
- 2025/07/31
- Product number
- SML1370
- Product name
- A-779 trifluoroacetate salt
- Purity
- ≥98% (HPLC)
- Packaging
- 25MG
- Price
- $462
- Updated
- 2025/07/31
- Product number
- A3281
- Product name
- A-779
- Packaging
- 25MG
- Price
- $151
- Updated
- 2025/07/31
- Product number
- A3281
- Product name
- A-779
- Packaging
- 100MG
- Price
- $416
- Updated
- 2025/07/31
- Product number
- 23396
- Product name
- A-779
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $25
- Updated
- 2021/12/16
(D-ALA7)-ANGIOTENSIN I/II (1-7) Chemical Properties,Usage,Production
Uses
A 779 is an angiotensin heptapeptide analog antagonist.
Biochem/physiol Actions
A-779 (D-Ala7-Ang-(1-7)) is a potent and selective antagonist of angiotensin (1-7), an endogenous peptide that acts through activation of a non-AT1, non-AT2 receptor, Mas, and opposes the activity of angiotensin. A-779 has an IC50 of 0.3 nM for Mas with negligible affinity for either AT1R or AT2R.
in vivo
Infusion of Ang(1-7) and A-779 (400 ng/kg/min, s.c.) alone or combined for 6 weeks does not prevent uterus atrophy or inhibit the body weight gain of OVX rats. A-779 markedly elevates serum bone specific alkaline phosphatase (BALP), telopeptides of collagen type I (CTX), tartarate resistant acid phosphatase (TRAcP 5b), osteocalcin (OC) and urinary deoxypyridinoline (DPD). Infusion of Ang(1-7) and/or A-779 does not significantly change serum minerals concentrations in sham or OVX groups. A-779 in the OVX animals does not change AngII, Ang(1-7), AT1R, AT2R, ACE, ACE-2, Mas receptor, RANKL and OPG proteins expressions in relation to OVX group, while AngII (P < 0.05), AT1R (P < 0.05), ACE (P < 0.01) and RANKL (P < 0.01) expressions are significantly higher and Ang(1-7), AT2R, ACE-2, MasR and OPG are significantly (P < 0.01) lower than sham group. Blocking of the G-protein coupled receptor (Mas) by A-779 markedly abolishes Ang(1-7) favorable effects on bone health suggesting the vital role of Mas receptor in mediating Ang(1-7) osteo-protective effects[1]. Inhibition of Ang1-7 cascade by A-779 (400 ng/kg/min) significantly eradicates captopril protective effects on bone metabolism, mineralization and micro-structure. A-779 also restores OVX effects on RANKL expression and ACE-1/AngII/AT1R cascade and down-regulates OPG expression and ACE-2/Ang1-7/Mas pathway[2].
IC 50
AT2 Receptor; AT1 Receptor
storage
Store at -20°C
(D-ALA7)-ANGIOTENSIN I/II (1-7) Preparation Products And Raw materials
Raw materials
Preparation Products
(D-ALA7)-ANGIOTENSIN I/II (1-7) Suppliers
- Tel
- --
- Fax
- --
- brunschwig@brunschwig.nl
- Country
- The Netherlands
- ProdList
- 4996
- Advantage
- 67